Dr. Bruce Katz, MD, shares some emerging treatments in dermatology including:

1. The global facial injectables market size is expected to reach USD 9.07 billion by 2028 (the market size stood at USD 4.46 billion in 2020): What does this mean for aesthetic medicine providers, are there more ways to capitalize on this growth other than simply offering injectables?

2. Which new or emerging laser technology or treatment should providers have their eyes on, or consider offering in their practice if they don’t already?

3. For someone interested in facial rejuvenation but hesitant to commit to surgery, which noninvasive or minimally invasive procedure delivers the best results with little downtime?

4. You practice both clinical and aesthetic dermatology – which field has the most growth potential for new practitioners? If a dermatology student or resident were deciding between dermatologic subspecialties, what would your advice to them be?

5. Your partnership with LiVDerm as faculty at many of our prestigious events draws quite a following. What do you think LiVDerm offers our attendees that other conferences do not? What are providers who’ve never been to a LiVDerm event missing?

6. February is Black History Month – LiVDerm has dedicated resources and programming to address dermatologic conditions that disproportionately affect or burden people with skin of color (SOC) such as African Americans. What is your experience in this area, and how can the dermatology community lessen these disparities?

Brett King, MD, LivDerm faculty and a pioneer in utilizing JAK inhibitor therapy for treating atopic dermatitis discusses the best ways recently approved JAK inhibitors can be used in your clinical toolbox.

Dr. Peter Lio, MD, shares some highlights about the treatment of atopic dermatitis in pediatric patients including:

1. Can you tell us about the number of emerging therapies for the treatment of atopic dermatitis in pediatric patients and how this has changed the treatment landscape?

2. What is your personal approach to treating atopic dermatitis in pediatric patients?

3. What made you decide to found the Chicago Integrative Eczema Center to prevent atopic dermatitis in children?

4. Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric atopic dermatitis patients regarding treatment options?

5. Are there any other tips that you recommend to your patients when explaining to them how to manage their skin diseases?

6. If you could be known for one thing, what would it be?!

Candrice Heath, MD, discusses key takeaways regarding disparities in the treatment of atopic dermatitis and scalp/hair conditions in pediatric patients with skin of color, including:

• Can you highlight some of the systemic issues that contribute to a lack of knowledge about atopic dermatitis in patients of color, particularly in the pediatric patient population? (This is in reference to lack of diversity in clinical trials, lack of training involving skin of color, etc.)
• Can you discuss some of the more common hair and scalp conditions seen in pediatric patients of color, and why they are more commonly seen or more severe in patients of color?
• Are there any unique considerations that must be taken when discussing these conditions with the parents and caregivers in this patient population?
• Can you tell us which treatments for atopic dermatitis have been studied specifically in patients of color? Do you know if any of these treatments been studied specifically in pediatric patients of color?
• Is there anything else you’d like to add?

Susan Taylor, MD, shares some clinical pearls from regarding the treatment of acne patients with skin of color, including:

• Can you highlight some of the systemic issues that contribute to a lack of knowledge about acne in patients of color? (This is in reference to lack of diversity in clinical trials, lack of training involving skin of color, etc.)
• Can you explain why it is important to treat post-inflammatory hyperpigmentation alongside acne, particularly in patients of color?
• Are there any unique considerations that must be taken when prescribing treatment for acne patients with skin of color?
• Can you tell us which acne treatments have been studied specifically in patients of color, and briefly touch upon the safety and efficacy of those treatments?
• Is there anything else you’d like to add?

Andrew Alexis, MD, shares some highlights regarding the treatment of atopic dermatitis and psoriasis in patients with skin of color, including:

• Can you highlight some of the systemic issues that contribute to a lack of knowledge about acne in patients of color? (This is in reference to lack of diversity in clinical trials, lack of training involving skin of color, etc.)
• Can you explain why certain skin conditions, including atopic dermatitis and psoriasis, may be more difficult to diagnose in patients with skin of color?
• What is your personal approach to treating atopic dermatitis patients with skin of color?
• In what ways do you feel that dermatologists can continue to improve in caring for patients with skin of color?
• Is there anything else you’d like to add?

Amy McMichael, MD, Chair of the LiVDerm Deep Dive Racial Disparities in Dermatology program, shares highlights the current health disparities in dermatologic care for patients with skin of color, including:

• Can you give us a brief overview of the LiVDerm Deep Dive Racial Disparities program and why it is important to dermatologists? 
• Can you highlight some of the systemic issues that specifically contribute to a lack of knowledge about dermatologic conditions in patients of color?
• Have you seen a change in the representation of patients with skin of color in clinical trials?
• Where do you feel dermatologists can continue to improve in terms of recognizing disparities and treating patients with skin of color?
• Is there anything else you'd like to add?

Mark Lebwohl, MD, discusses the new and emerging therapies for treatment of psoriasis, including:

Can you elaborate on the different classes of biologics currently indicated for treatment of psoriasis?

• What are some of the most promising therapies that will likely be part of the psoriasis treatment table in the near future?
• Do you foresee that they will be also approved for pediatric psoriasis patients, or only for the adult population?
• Where do you feel biologics fit in with the other approved treatments for psoriasis, or overall in the treatment regimen?
• Can you tell us what you feel is still needed in terms of developing new treatments for psoriasis?

Adelaide Hebert, MD, shares some highlights and clinical pearls about treatment of psoriasis in pediatric patients, including:

• What is your personal approach to treating psoriasis in pediatric patients compared to other age groups?
• Can you highlight the different class of therapeutics currently indicated to treat pediatric patients with psoriasis?
• Are there any considerations to be made when prescribing treatment for psoriasis in patients across the age spectrum, from infants to adolescents?
• How do you educate patients and families to deal with the psychological aspects of psoriasis, as well as with treatment adherence?

Latanya Benjamin, MD, shares clinical pearls about the management of atopic dermatitis in pediatric patients with skin of color, including:

• Can you tell us about the number of emerging therapies for treatment of AD in pediatric patients and how this will change the treatment landscape?
• What is your personal approach to treating AD in pediatric patients with skin of color?
• Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?